FLEXERIL Drug Patent Profile

Which patents cover Flexeril, and when can generic versions of Flexeril launch?

Flexeril is a drug marketed by Janssen Res And Dev and is included in one NDA.

The generic ingredient in FLEXERIL is cyclobenzaprine hydrochloride. There is one drug master file entry for this compound. Sixty suppliers are listed for this compound. Additional details are available on the cyclobenzaprine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Flexeril

A generic version of FLEXERIL was approved as cyclobenzaprine hydrochloride by ACTAVIS LABS FL INC on May 3^rd, 1989.

Summary for FLEXERIL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	9
Patent Applications:	1,456
DailyMed Link:	FLEXERIL at DailyMed

Recent Clinical Trials for FLEXERIL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Augusta University	Phase 4
Neurana Pharmaceuticals, Inc.	Phase 1
Cognitive Research Corporation	Phase 1

See all FLEXERIL clinical trials

US Patents and Regulatory Information for FLEXERIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Res And Dev	FLEXERIL	cyclobenzaprine hydrochloride	TABLET;ORAL	017821-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Janssen Res And Dev	FLEXERIL	cyclobenzaprine hydrochloride	TABLET;ORAL	017821-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for FLEXERIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Res And Dev	FLEXERIL	cyclobenzaprine hydrochloride	TABLET;ORAL	017821-001	Approved Prior to Jan 1, 1982
Janssen Res And Dev	FLEXERIL	cyclobenzaprine hydrochloride	TABLET;ORAL	017821-002	Approved Prior to Jan 1, 1982
Janssen Res And Dev	FLEXERIL	cyclobenzaprine hydrochloride	TABLET;ORAL	017821-002	Approved Prior to Jan 1, 1982
Janssen Res And Dev	FLEXERIL	cyclobenzaprine hydrochloride	TABLET;ORAL	017821-001	Approved Prior to Jan 1, 1982

Flexeril Market Dynamics and Financial Trajectory: Cyclobenzaprine Patent, Generic, and Commercial Analysis

Last updated: September 25, 2026

Flexeril is the former U.S. brand name for cyclobenzaprine hydrochloride, a centrally acting skeletal-muscle relaxant. Its branded commercial opportunity ended after loss of market exclusivity, and the U.S. market is now supplied primarily by low-cost generic tablets. Flexeril has no meaningful current brand revenue, no material active patent barrier to generic entry, and limited pricing power.

The commercial market has shifted from branded prescription sales to high-volume, low-margin generic dispensing. Growth is constrained by short treatment duration, competition from alternative muscle relaxants, safety concerns in older adults, and increasing use of nonpharmacologic treatment for acute back and neck pain.

What is Flexeril and how is cyclobenzaprine used?

Flexeril is the former brand formulation of cyclobenzaprine hydrochloride immediate-release tablets. The FDA approved cyclobenzaprine for relief of muscle spasm associated with acute, painful musculoskeletal conditions. The drug is intended for short-term use, generally up to two or three weeks, and is prescribed alongside rest and physical therapy rather than as a stand-alone treatment.[1]

Attribute	Flexeril and cyclobenzaprine
Active ingredient	Cyclobenzaprine hydrochloride
Drug class	Centrally acting skeletal-muscle relaxant
Original U.S. brand	Flexeril
Common immediate-release strengths	5 mg and 10 mg tablets
Additional generic strength	7.5 mg tablet
Route	Oral
FDA indication	Acute, painful musculoskeletal conditions
Typical treatment period	Up to two or three weeks
Federal controlled-substance status	Not scheduled under the federal Controlled Substances Act
Current U.S. market	Predominantly generic
Current brand position	Flexeril is not a significant active commercial brand

Cyclobenzaprine is structurally related to tricyclic antidepressants and has anticholinergic and sedating effects. Common adverse effects include drowsiness, dry mouth, dizziness, and fatigue. The American Geriatrics Society lists cyclobenzaprine among medications generally to avoid in older adults because of anticholinergic effects, sedation, and fracture risk.[2]

When did Flexeril lose exclusivity and patent protection?

Flexeril lost its commercially relevant exclusivity decades ago. The original immediate-release product was approved in the late 1970s, and generic cyclobenzaprine entered the U.S. market after the underlying branded protection and regulatory exclusivity had expired.

The practical result is that Flexeril is no longer protected by an enforceable market barrier comparable to a recently approved branded drug. Generic manufacturers can market cyclobenzaprine immediate-release tablets through abbreviated new drug applications, subject to FDA approval and applicable labeling requirements.

Flexeril exclusivity timeline

Period	Market event	Commercial effect
1970s	Original Flexeril approval and commercial launch	Brand-led market
1980s-1990s	Expansion of branded prescribing	Increasing physician familiarity
Late 1990s onward	Generic cyclobenzaprine availability	Rapid erosion of brand pricing
2000s	Generic suppliers become the primary U.S. source	Commodity market structure
2010s	Extended-release and lower-dose alternatives appear	Fragmentation of product positioning
2020s	Immediate-release generic remains widely available	Minimal brand economics

The FDA’s Orange Book remains the principal source for approved drug products, patent listings, and regulatory exclusivity information. Flexeril’s commercial position does not depend on a live Orange Book patent estate capable of blocking generic immediate-release entry.[3]

What patents protect Flexeril and cyclobenzaprine products?

No material active patent estate protects the conventional Flexeril immediate-release tablet market in the United States.

The original composition and product protection associated with cyclobenzaprine expired long ago. Later patent activity focused primarily on modified-release delivery systems and related formulations rather than on the basic cyclobenzaprine molecule.

Formulation patents and extended-release products

The most important later product was Amrix, an extended-release cyclobenzaprine product marketed in 15 mg and 30 mg capsule strengths. Amrix used a modified-release delivery system intended to provide once-daily dosing. Its commercial opportunity was based on formulation differentiation, not a new active ingredient.

The extended-release category created a temporary patent and regulatory barrier around the specific delivery technology. That barrier did not restore exclusivity to immediate-release Flexeril or prevent generic manufacturers from selling conventional 5 mg and 10 mg tablets.

Product category	Patent position	Current commercial implication
Immediate-release cyclobenzaprine tablets	Core protection expired	Open generic competition
Extended-release cyclobenzaprine	Formulation patents and regulatory exclusivity were time-limited	Limited historical differentiation
Branded Flexeril	No meaningful current patent moat	No sustainable brand pricing
Generic cyclobenzaprine	ANDA-based competition	Price-driven market

The relevant intellectual-property distinction is between molecule protection and formulation protection. Cyclobenzaprine’s molecule-level protection no longer supports premium economics. Formulation patents may have delayed competition for particular extended-release products, but they do not protect the overall cyclobenzaprine market.

What is the Orange Book status of Flexeril?

Flexeril has no commercially meaningful current Orange Book position that prevents generic substitution for immediate-release cyclobenzaprine.

The FDA’s Orange Book records approved products, therapeutic equivalence evaluations, patent listings, and exclusivity data. Generic cyclobenzaprine products are generally evaluated against the applicable reference-listed drug through the ANDA pathway. Once relevant patents and exclusivities expire, approved generics can receive an “A” therapeutic-equivalence rating when they meet FDA requirements.[3]

The practical Orange Book conclusion is straightforward:

1. Immediate-release cyclobenzaprine is an established generic market.
2. The former Flexeril brand does not control current distribution.
3. Patent litigation risk is low for the basic tablet market.
4. Any remaining intellectual-property questions are product-specific and more likely to involve modified release, labeling, or manufacturing than the original Flexeril molecule.

Are there Paragraph IV challenges to Flexeril?

Paragraph IV litigation is not a current commercial issue for the original Flexeril immediate-release product.

Paragraph IV certifications arise when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or not infringed. Such disputes are common when a branded drug has live Orange Book patents. Cyclobenzaprine immediate-release tablets are too mature for that framework to create a meaningful current barrier.

Historical disputes may have affected extended-release cyclobenzaprine products, particularly Amrix and related generic versions. Those disputes are separate from the current immediate-release generic market. A company evaluating cyclobenzaprine today would focus on ANDA approval, manufacturing economics, supply reliability, and state-level substitution rather than on a Paragraph IV strategy against Flexeril.

What is the FDA regulatory status of cyclobenzaprine?

Cyclobenzaprine remains an FDA-approved prescription drug, but Flexeril is no longer the economically important product.

FDA-approved generic cyclobenzaprine products are available in immediate-release tablet strengths, including 5 mg and 10 mg. The 5 mg dose is clinically relevant because it may reduce sedation relative to higher doses while preserving therapeutic utility for some patients. A 7.5 mg generic strength also exists in the U.S. market.

The principal regulatory constraints are clinical and labeling-related:

• Use is limited to acute musculoskeletal conditions.
• Treatment beyond two or three weeks is generally not supported by adequate evidence.
• Sedation can impair driving and operating machinery.
• Alcohol and other central-nervous-system depressants can increase impairment.
• Serotonergic drugs can raise concern for serotonin syndrome.
• Older adults face greater anticholinergic and fall-related risk.
• Cyclobenzaprine is not a treatment for spasticity associated with cerebral or spinal cord disease.

The FDA label also warns against use in patients with certain cardiac conditions and against concomitant use with monoamine oxidase inhibitors.[1]

How large is the cyclobenzaprine market?

Cyclobenzaprine remains one of the most frequently prescribed skeletal-muscle relaxants in the United States, but prescription volume does not translate into strong manufacturer revenue because the product is generic and low priced.

Public sources do not provide a current, audited standalone revenue figure for Flexeril because the brand is not reported as an active material product line by a major public pharmaceutical company. Market-size estimates vary according to whether they count prescriptions, extended-release products, institutional sales, retail dollars, or all cyclobenzaprine formulations.

The market’s financial structure is better described through its revenue drivers:

Financial driver	Directional effect
High prescription volume	Supports unit demand
Generic substitution	Reduces average selling price
Multiple suppliers	Compresses gross margin
Short treatment duration	Limits repeat use
Low manufacturing complexity	Increases supplier competition
Retail and pharmacy purchasing pressure	Transfers value away from manufacturers
Limited brand differentiation	Prevents premium pricing
Periodic shortages	Can temporarily improve supplier pricing

For generic manufacturers, cyclobenzaprine can provide steady base-load volume, but it is unlikely to be a major growth product unless a supplier secures a differentiated dosage form, a reliable supply position, or a specialized distribution contract.

What companies compete in the cyclobenzaprine market?

The U.S. market includes multiple generic manufacturers and labelers. Product availability changes as companies enter, exit, acquire portfolios, or discontinue individual presentations. Major generic companies that have marketed cyclobenzaprine products or related skeletal-muscle-relaxant products include:

• Teva Pharmaceuticals
• Sandoz
• Hikma Pharmaceuticals
• Rising Pharmaceuticals
• Amneal Pharmaceuticals
• Solco Healthcare
• Zydus Pharmaceuticals
• Dr. Reddy’s Laboratories
• Endo and legacy Par Pharmaceutical businesses
• Other FDA-approved generic labelers

The competitive basis is primarily price, quality compliance, fill-rate reliability, and pharmacy-channel access. Brand promotion has little influence on the immediate-release market.

How does cyclobenzaprine compare with other muscle relaxants?

Drug	Market position	Key commercial characteristic
Cyclobenzaprine	High-volume generic	Mature, low-cost, familiar
Methocarbamol	High-volume generic	Direct substitute in acute muscle spasm
Tizanidine	Generic	Useful where spasticity and muscle tone are concerns
Baclofen	Generic	More associated with spasticity than routine acute back pain
Carisoprodol	Generic	Controlled substance with abuse and dependence concerns
Orphenadrine	Generic	Smaller and more specialized market
Chlorzoxazone	Generic	Older, lower-volume alternative

Cyclobenzaprine competes most directly with methocarbamol and tizanidine. Prescribing decisions are influenced by sedation, dosing frequency, drug interactions, age, comorbidities, and clinician familiarity. No product has a durable patent-based advantage in the mature generic segment.

What generic entry risks exist for Flexeril?

Generic entry risk is effectively realized rather than prospective. Immediate-release cyclobenzaprine has already experienced full generic penetration.

The principal risks have shifted from entry to market erosion and supply dynamics:

1. Price erosion: Multiple suppliers can drive prices toward marginal manufacturing cost.
2. Channel concentration: Retail chains, wholesalers, and pharmacy-benefit managers can pressure suppliers.
3. Low switching costs: Pharmacies can substitute among therapeutically equivalent products.
4. Contract loss: A manufacturer may lose volume after a wholesaler or group purchasing organization changes suppliers.
5. FDA compliance exposure: Manufacturing observations, warning letters, or recalls can remove capacity from the market.
6. Shortage volatility: A recall or plant disruption can temporarily increase prices, but the effect may not persist.
7. Clinical substitution: Physicians may choose methocarbamol, tizanidine, or nonpharmacologic treatment.

Generic entry risk is therefore high for any late entrant seeking attractive margins. A new manufacturer would need cost advantages, an underrepresented strength, dependable supply, or a differentiated release profile.

What patent litigation affects Flexeril?

No current litigation involving the original Flexeril immediate-release product materially changes the U.S. competitive landscape.

Historical litigation risk was more relevant to extended-release cyclobenzaprine products, where formulation patents and bioequivalence issues could affect generic timing. For conventional tablets, the litigation profile is low because:

• The active ingredient is old.
• The principal dosage forms are established.
• Generic products have long been approved.
• No current branded launch depends on excluding generic cyclobenzaprine.
• Commercial disputes are more likely to involve contracts, pricing, recalls, or supply than patent infringement.

What licensing deals and acquisitions affect cyclobenzaprine?

Flexeril does not have an active licensing-driven growth story. The original branded product passed through historical ownership and commercialization arrangements, while later extended-release products involved separate commercial rights and formulation assets.

Current commercial value resides primarily in generic product authorizations, manufacturing capacity, and distribution agreements. Generic companies typically do not disclose product-level licensing economics for mature products such as cyclobenzaprine. There is no publicly established licensing transaction that gives one company a durable monopoly over the current immediate-release market.

For investors and business-development teams, a cyclobenzaprine transaction would be assessed as a portfolio or manufacturing deal rather than as a branded licensing opportunity. Relevant diligence points include:

• ANDA ownership and transfer history
• FDA inspection status
• Manufacturing location
• API source and dual-sourcing capacity
• Product-specific recalls
• Current wholesale acquisition price
• Net price after rebates and chargebacks
• Customer concentration
• Therapeutic-equivalence rating
• Remaining product liability exposure

How strong is the Flexeril patent estate?

The patent estate is weak for immediate-release cyclobenzaprine and has no meaningful ability to support branded pricing.

Patent-estate factor	Assessment
Molecule protection	Expired
Immediate-release tablet protection	Expired or commercially irrelevant
Extended-release formulation protection	Historically relevant but time-limited
Current Orange Book leverage	Low
Paragraph IV leverage	Low
Generic substitution risk	Already realized
Manufacturing barriers	Low to moderate
Regulatory complexity	Low for established immediate-release products
Commercial durability	Volume-based, not IP-based

Manufacturing can still create operational barriers. A supplier with validated processes, reliable API procurement, and a strong FDA compliance record can outperform competitors. Those barriers are practical rather than patent-based and generally do not support sustained monopoly pricing.

What is the likely financial trajectory for Flexeril and cyclobenzaprine?

The branded Flexeril financial trajectory is effectively complete. The brand does not have a credible path to regain meaningful revenue without a new formulation, a new indication, or a relaunch supported by a differentiated commercial strategy.

The generic cyclobenzaprine trajectory is more stable but low growth:

• Prescription demand should remain supported by common acute musculoskeletal complaints.
• Dollar sales will remain exposed to generic price compression.
• Volume growth is unlikely to generate proportional revenue growth.
• Extended-release products may provide limited differentiation but face their own generic competition.
• Safety concerns in older adults and opioid-sparing treatment discussions can produce both demand support and prescribing limitations.
• Payers and pharmacies will continue to favor low-cost generic supply.

A reasonable commercial classification is “mature, high-volume, low-margin generic.” The product can contribute cash flow to a scaled generic portfolio, but it is unlikely to create material enterprise value as a stand-alone asset.

Key Takeaways

• Flexeril is the former brand name for cyclobenzaprine hydrochloride.
• The original immediate-release product lost meaningful exclusivity decades ago.
• Generic cyclobenzaprine dominates the U.S. market.
• There is no material current patent barrier to immediate-release generic entry.
• Historical formulation protection was more relevant to extended-release products such as Amrix.
• Flexeril has no meaningful current branded revenue base.
• Market economics depend on manufacturing cost, supply reliability, pharmacy access, and generic pricing.
• Cyclobenzaprine competes mainly with methocarbamol and other generic muscle relaxants.
• Patent litigation and Paragraph IV risk are low for the conventional tablet market.
• The product’s financial outlook is stable in volume but structurally weak in pricing and margin.

FAQs About Flexeril Market Exclusivity and Commercial Value

Is Flexeril still sold as a brand-name drug in the United States?

Flexeril is not a significant active brand in the U.S. market. Prescriptions are generally filled with generic cyclobenzaprine hydrochloride.

Can a generic manufacturer still obtain exclusivity for cyclobenzaprine?

A new generic product may receive limited regulatory benefits in specific circumstances, but conventional cyclobenzaprine tablets do not offer an attractive route to durable exclusivity because the market is mature and heavily supplied.

Did Amrix extend Flexeril’s patent life?

No. Amrix was an extended-release cyclobenzaprine product with separate formulation and delivery characteristics. Its historical protection did not extend the core patent life of immediate-release Flexeril.

Is cyclobenzaprine a controlled substance?

Cyclobenzaprine is not federally scheduled as a controlled substance under the Controlled Substances Act, although it can cause sedation, impairment, and misuse-related concerns.

Could Flexeril generate meaningful revenue through a relaunch?

A relaunch would face substantial barriers from generic substitution, low pricing, limited treatment duration, and established alternatives. Meaningful revenue would require a differentiated formulation, a defensible delivery technology, or a new clinical use with regulatory support.

References

1. U.S. Food and Drug Administration. (n.d.). Cyclobenzaprine hydrochloride prescribing information. DailyMed. https://dailymed.nlm.nih.gov/

2. American Geriatrics Society Beers Criteria Update Expert Panel. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society, 71(7), 2052-2081. https://doi.org/10.1111/jgs.18372

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

5. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-andaoviotized